OPIOID USE DISORDER TREATMENTS PRIOR AUTHORIZATION FORM



 Keystone First
 PERFORM

 Community HealthChoices
 Next Generation Pharmacy Beneficial Statements

Next Generation Pharmacy Benefits

(form effective 7/10/23)

Fax to PerformRx[™] at **1-855-851-4058**, or to speak to a representative, call **1-866-907-7088**.

	I		
□ New request □ Renewal request Total # of pages:		Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
Facility contact name/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:
CLINICAL INFORMATION			
Drug requested:		Strength:	Dosage form:
Directions:		Quantity:	Requested duration:
Diagnosis (<u>submit documentation</u>):			Dx code (<u>required</u>):
Pennsylvania law requires prescribers to query the PA PDMP each time a patient is prescribed an opioid drug product or benzodiazepine.			
 Naloxone is available at Pennsylvania pharmacies via standing order from the Secretary of the Department of Health. Pennsylvania Medical Assistance beneficiaries may obtain naloxone <u>free-of-charge</u> through their prescription drug benefit. 			
Complete all sections that apply to the beneficiary and this request.			
Check all that apply and <u>submit documentation</u> for each item.			
 For a NON-PREFERRED SUBLINGUAL buprenorphine product (e.g., film, tablet): Tried and failed or has a contraindication or an intolerance to the preferred SUBLINGUAL buprenorphine Opioid Use Disorder Treatments (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.) List preferred medications tried: 			
 2. For a non-preferred NON-SUBLINGUAL buprenorphine product (e.g., injection): Tried and failed or has a contraindication or an intolerance to the preferred NON-SUBLINGUAL buprenorphine Opioid Use Disorder Treatments (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.) List preferred medications tried: 			
3. For Lucemyra (lofexidine):			
 4. For a SUBLINGUAL buprenorphine product ABOVE THE DAILY DOSE LIMIT OF 24 MG of buprenorphine per day: Is prescribed a daily dose consistent with medically accepted prescribing practices and standards of care Had an unsatisfactory clinical response (e.g., uncontrolled withdrawal or cravings) at the current quantity limit of 24 mg per day If already established on buprenorphine, has results of a recent UDS demonstrating compliance with sublingual buprenorphine therapy 			
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION			
Prescriber signature:			Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.